Plain-English translation of NCT07199296 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether — a new type of targeted cancer medication — works better when combined with rituximab, a standard lymphoma treatment. Some patients may also receive an optional stem cell transplant as part of their care. The study wants to know if this combination helps patients with newly diagnosed mantle cell lymphoma achieve better responses and have fewer side effects.
Mantle cell lymphoma is a serious cancer that needs strong treatments, but current options don't work equally well for all patients. This trial is testing whether the new medication can improve how many people respond to treatment and how long they stay in remission.
You likely qualify if…
You likely don't qualify if…
You would take the new medication by mouth once daily for about 6 months (the induction phase) while also receiving rituximab infusions at a clinic. If your cancer responds well and you meet criteria, you may choose to have a stem cell transplant with special chemotherapy preparation. After that, you would continue taking the medication daily until your cancer progresses or side effects become too difficult. Throughout the trial, you'll have regular blood tests and scans to monitor how you're responding.
AI-generated summary from trial data · Jun 15, 2026 · Not medical advice
China